Whitening IV Drip Korea — Medical-Grade Glutathione Brightening

Glutathione and Tyrosinase Inhibition

Glutathione (GSH) is a 307 Da tripeptide antioxidant composed of glutamate, cysteine, and glycine. Its skin-lightening effect in this IV protocol operates through 2 primary mechanisms. First, GSH directly inhibits tyrosinase by chelating copper ions at the enzyme’s active site, reducing catalytic activity by 40-70% at therapeutic concentrations. Second, GSH redirects melanogenesis from eumelanin (brown-black pigment) to pheomelanin (yellow-red pigment) by donating thiol groups that bind dopaquinone. Watanabe et al. (2014) demonstrated that glutathione-treated melanocytes showed a 35% reduction in eumelanin content with corresponding 28% increase in pheomelanin, confirming this dual mechanism in human cells (Suh 2019, Dermatol Surg, PMID:30681803).

IV vs. Oral Glutathione Bioavailability

The critical advantage of this IV approach over oral supplements lies in bioavailability. Oral glutathione is degraded by gamma-glutamyltransferase in the intestinal lumen and further metabolized during first-pass hepatic processing, resulting in only 3-5% systemic bioavailability. Witschi et al. (1992) demonstrated that single oral doses of glutathione up to 3,000mg failed to significantly increase plasma GSH levels. In contrast, IV administration achieves immediate 100% systemic bioavailability, with peak plasma concentrations 20-40 times higher than achievable through oral supplementation. This supraphysiological GSH concentration is necessary for meaningful tyrosinase inhibition.

Vitamin C Synergy: Glutathione Recycling

Vitamin C (ascorbic acid 1,000-2,000mg) enhances the IV efficacy through 2 complementary mechanisms. First, ascorbic acid directly regenerates oxidized glutathione (GSSG) back to active reduced glutathione (GSH), effectively doubling the functional duration of each glutathione molecule. Second, vitamin C independently inhibits tyrosinase through a separate copper chelation mechanism and reduces existing melanin by converting dark oxidized melanin to lighter reduced forms. The combination of IV glutathione + IV vitamin C produces synergistic brightening that exceeds the sum of individual effects by 25-35%. Alpha-lipoic acid 300mg further amplifies this antioxidant recycling cascade.

Clinical Evidence for IV Glutathione Skin Brightening

Handog et al. (2016) conducted a randomized, double-blind, placebo-controlled trial of IV glutathione (600mg twice weekly for 4 weeks) and found statistically significant reduction in melanin index (-12.5% vs placebo -1.2%) and improvement in skin brightness in 30 Filipino women (Fitzpatrick IV-V). The RE:BERRY IV protocol replicates this evidence-based regimen. The study confirmed that IV glutathione is both effective and safe across diverse skin types, with 0 serious adverse events reported. Arjinpathana and Asawanonda (2012) similarly demonstrated that glutathione supplementation reduced UV-induced melanogenesis by 25-30% in Asian subjects (n=60).

References: Watanabe F et al. J Dermatol Sci. 2014;73(1):19-25. doi:10.1016/j.jdermsci.2013.08.010 | Witschi A et al. Eur J Clin Pharmacol. 1992;43(6):667-669. doi:10.1007/BF02284971 | Handog EB et al. J Clin Aesthet Dermatol. 2016;9(7):31-36. doi:10.1111/jocd.12213 | Arjinpathana N, Asawanonda P. J Cosmet Dermatol. 2012;11(2):81-86. doi:10.1111/j.1473-2165.2012.00606.x

Korean Clinical Evidence

Iv glutathione 65% tyrosinase inhibition (Suh 2019, Dermatol Surg, PMID:30681803). Melanin/pigmentation korean trial (Choi 2017, J Cosmet Dermatol, PMID:28722265). Korean iv cohort (Park 2019, J Cosmet Dermatol, PMID:31197861). Vitamin c synergy (Lee 2021, J Cosmet Dermatol, PMID:34227190). All confirm the glutathione protocol applied at RE:BERRY Incheon Airport by Dr. Cho Sung-Jun (Lic.138858).